Govt Bans Cough & Cold Medicine Combo for Children Under 4 Years
Source: ET Real Estate
Arth Insight · What this means for your wallet
- You may need to purchase alternative, potentially different-priced, cough and cold medicines for young children.
- Expect to incur pediatrician consultation fees to get safe and appropriate prescriptions for children under 4.
- Any existing stock of these banned FDC medicines for children under 4 becomes unusable, representing a sunk cost.
The Indian government has prohibited the use of fixed-dose combinations containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride for children below four years of age. Manufacturers are now mandated to display clear warnings on all product packaging.
- ▸Medicines combining Chlorpheniramine Maleate and Phenylephrine Hydrochloride are now banned for children under four.
- ▸Manufacturers must add clear warnings to packaging for these specific drug combinations.
- ▸The decision follows recommendations from expert health committees.
- ▸Parents should always check medicine labels and consult doctors for young children's health issues.
- ✓Medicines combining Chlorpheniramine Maleate and Phenylephrine Hydrochloride are now banned for children under four.
- ✓Manufacturers must add clear warnings to packaging for these specific drug combinations.
- ✓The decision follows recommendations from expert health committees.
- ✓Parents should always check medicine labels and consult doctors for young children's health issues.
The Indian government has implemented a significant restriction on certain fixed-dose combination (FDC) medicines commonly used for cough and cold symptoms. These FDCs, which contain Chlorpheniramine Maleate and Phenylephrine Hydrochloride, are now explicitly prohibited for use in children under the age of four years.
This regulatory change, effective immediately upon its publication in the official gazette, mandates that all manufacturers of these specific drug combinations must prominently display a warning on their product packaging. The warning will alert consumers that the medicine is not suitable for young children.
Why the Restriction?
The decision to tighten these regulations stems from recommendations provided by an expert committee and the Drugs Technical Advisory Board. These bodies are responsible for evaluating the safety and efficacy of pharmaceutical products in India and advising the government on necessary policy changes. The move underscores a proactive approach to child safety in medication.
Impact on Consumers and Manufacturers
- For Parents: Parents and guardians should be aware of this new regulation and carefully check the labels of cough and cold medicines before administering them to children, especially those under four years old. It is crucial to consult a pediatrician for appropriate treatment options for young children.
- For Manufacturers: Pharmaceutical companies producing these FDCs must swiftly update their packaging and labeling to comply with the new government directive. Failure to do so could lead to regulatory penalties.
This restriction is part of ongoing efforts by the government to ensure the safety and appropriate use of medicines, particularly for vulnerable populations like young children. It highlights the importance of evidence-based recommendations from expert bodies in shaping public health policy.
This report is for informational purposes only and does not constitute medical advice. Always consult a healthcare professional.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
Which specific medicines are affected by this new government rule?
The new rule affects fixed-dose combination medicines that contain both Chlorpheniramine Maleate and Phenylephrine Hydrochloride.
For what age group is the use of these medicines now prohibited?
These specific fixed-dose combination medicines are now prohibited for use in children below four years of age.
What action must manufacturers take regarding these medicines?
Manufacturers are now required to clearly display a warning on all associated product packaging stating that these medicines are not for use in children under four years.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
BreakingEli Lilly to Launch Four New Weight-Loss Drugs, Sees Potential in Indian Biotech Despite Funding Lag
Pharmaceutical giant Eli Lilly, driven by the success of Mounjaro and Zepbound, aims to launch up to four new weight-loss products in the coming years. The company acknowledges India's strong biotechnology talent and expertise, but highlights existing challenges in the research funding environment. Eli Lilly has expressed openness to forming partnerships with Indian biotech firms for future collaborations.
ChrysCapital and Tata Capital Inject ₹584 Crore into Linux Laboratories
Linux Laboratories has secured approximately ₹584 crore ($70 million) in equity funding from investment giants ChrysCapital and Tata Capital Healthcare Fund III. This significant investment will enable Linux Laboratories to expand its presence in existing and new therapeutic areas within the healthcare sector.
BreakingSupreme Court Flags High Cancer Drug Prices, Urges Government Price Cap
The Supreme Court has expressed serious concern over the exorbitant pricing of essential medicines, particularly cancer drugs, sold with huge markups. Justices Vikram Nath and SVN Bhatti urged the government to consider a uniform pricing rule to cap Maximum Retail Prices (MRPs), highlighting the burden on ordinary people and taxpayers.
Related Stories
BreakingEli Lilly to Launch Four New Weight-Loss Drugs, Sees Potential in Indian Biotech Despite Funding Lag
Pharmaceutical giant Eli Lilly, driven by the success of Mounjaro and Zepbound, aims to launch up to four new weight-loss products in the coming years. The company acknowledges India's strong biotechnology talent and expertise, but highlights existing challenges in the research funding environment. Eli Lilly has expressed openness to forming partnerships with Indian biotech firms for future collaborations.
ChrysCapital and Tata Capital Inject ₹584 Crore into Linux Laboratories
Linux Laboratories has secured approximately ₹584 crore ($70 million) in equity funding from investment giants ChrysCapital and Tata Capital Healthcare Fund III. This significant investment will enable Linux Laboratories to expand its presence in existing and new therapeutic areas within the healthcare sector.
BreakingSupreme Court Flags High Cancer Drug Prices, Urges Government Price Cap
The Supreme Court has expressed serious concern over the exorbitant pricing of essential medicines, particularly cancer drugs, sold with huge markups. Justices Vikram Nath and SVN Bhatti urged the government to consider a uniform pricing rule to cap Maximum Retail Prices (MRPs), highlighting the burden on ordinary people and taxpayers.
BreakingNiti Aayog Plans National Quality Grades for Hospitals to Boost Patient Choice
Niti Aayog is developing a national quality framework to grade both public and private hospitals in India. This initiative aims to help patients compare healthcare providers more easily and improve overall quality standards. The framework will assess factors like patient safety, clinical outcomes, and readmission rates.